B-hPD-1/hCTLA4 Mice

Basic Information

Strain Name
C57BL/6-Pdcd1tm1(PDCD1) Ctla4tm1(CTLA4)/Bcgen
Stock Number
120519
Common Name
B-hPD-1/hCTLA4 Mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
PD-1(Programmed death-1); CTLA4 (Cytotoxic T-lymphocyte-associated protein 4, CD152)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous

Targeting Strategy

Details

Phenotype

Protein Expression Analysis

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1 /hCTLA4 mice were analyzed by flow cytometry. Mouse CTLA4+ T cells were detectable in the WT mice, while human CTLA4+ T cells were detectable in the homozygous B-hPD-1 /hCTLA4 mice.

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1 /hCTLA4 mice were analyzed by flow cytometry. Mouse PD-1+ T cells were detectable in the WT mice, while human PD-1+ T cells were detectable in the homozygous B-hPD-1 /hCTLA4 mice.

Application

Combination therapy of PD-1 (Keytruda) mAb and CTLA4 (Yervoy) mAb (MC38 cell line)

B-hPD-1hCTLA4 Mice

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hCTLA4 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=5). Anti-hCTLA4 antibody Yervoy and the anti-hPD-1 antibody Keytruda show modest inhibition of tumor growth. On the other hand, combination of anti-hCTLA4 antibody Yervoy and the anti-hPD-1 antibody Keytruda shows almost complete inhibition when compared to single Ab treatment. B-hPD-1/hCTLA4 mouse model is a powerful tool for in vivo evaluation of combination therapy efficacy for hPD-1 antibodies and hCTLA4 antibodies . (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

  1. 1. Cell Research (2018) 0:1–15; doi: 10.1038/s41422-018-0012-z
  2. 2. Blood.2005;106:3127-3133
  3. 3. Scientific Reports volume7, 42913 (2017) doi: 10.1038/srep42913
  4. Nat Commun. 2017 Feb 6;8:14369. doi: 10.1038/ncomms14369.
  5. EMBO J. 1992 Nov;11(11):3887-95.
  6. J Exp Med. 2000 Oct 2;192(7):1027-34.
  7. Science. 2001 Jan 12;291(5502):319-22.
Back to top